Zoetis: The animal top dog with new therapies

Zoetis has shifted over the last 5–6 years from a high‑multiple "bulletproof compounder" that investors paid a premium for, to a solid but derated animal‑health leader dealing with growth and product‑specific scrutiny, with the stock recently trading well below its former highs and at 115.93 as of March 25, 2026.

2020–2021: Pandemic resilience and "premium compounder"

In 2020 Zoetis proved resilient through COVID, growing Q1 2020 revenue 5% year over year to $1.5 billion and Q3 2020 revenue 13%, while raising full‑year guidance as companion‑animal products (Simparica Trio, dermatology, vaccines, diagnostics) offset livestock weakness. Management highlighted strong operational growth (15% revenue, 20% adjusted net income in Q3) and emphasized increased pet ownership and medicalization, reinforcing a narrative of structurally higher pet spending. The stock trended steadily higher through 2020 into 2021, moving from the mid‑$100s in early 2020 to the mid‑$150s–$160s by late 2020 and climbing further into the high‑$100s by mid‑2021, reflecting confidence in its defensive growth profile.

In 2021 Zoetis reported its "strongest performance ever," with full‑year 2021 revenue up 15% operationally and adjusted net income up 19%, and guided to 9–11% operational revenue growth for 2022. Shares gained about 47% in 2021 as the company repeatedly beat expectations and raised guidance, cementing the view of Zoetis as a durable, high‑quality animal‑health franchise that could grow faster than the market. Technically, this period saw a strong uptrend with relatively shallow pullbacks, culminating in a sharp run into late 2021 where the stock peaked above $240 in December 2021 before signs of exhaustion and a later valuation reset.

2022: Peak to derating amid macro and growth concerns

In early 2022 Zoetis entered the year at elevated valuation levels after its 2021 surge, but broader risk‑off sentiment and a pullback in growth and high‑multiple names weighed on shares, which retreated from around $200 in January 2022 toward the mid‑$170s by mid‑year. The company continued to post solid growth, but the step‑down from 2021's "blowout" numbers and increasing macro uncertainty (rates, inflation, pressure on high‑multiple defensives) led investors to question how long premium growth could be maintained. Public narrative shifted from pure "hype growth story" toward "still‑great business but fully priced," as multiple compression, not collapse in fundamentals, drove much of the share‑price decline.

By late 2022, the stock had fallen from its 2021 highs in the mid‑$240s to the mid‑$140s–$150s, with December 2022 prices around the mid‑$140s, representing a large drawdown despite continued profitability and market leadership. Investor commentary increasingly framed Zoetis as a high‑quality animal‑health leader whose valuation was normalizing toward more standard growth multiples rather than bubble territory. Technically, 2022 was characterized by a prolonged downtrend from January into autumn, followed by a stabilization phase around the mid‑$140s–$150s where the stock began forming a base.

2023–2024: Recovery as defensive growth, then renewed pressure

Through 2023, Zoetis shares recovered from their 2022 lows, rising from the mid‑$140s in late 2022 to the mid‑$180s–$190s by mid‑2023 as markets stabilized and investors gravitated back to high‑quality, recurring‑revenue names. Quarterly results showed steady performance in companion‑animal and livestock portfolios, and the stock's narrative shifted toward a defensive compounder again, though with less exuberance than in 2021 as investors remained valuation‑sensitive. The chart during 2023 shows an uptrend with higher highs and higher lows into mid‑year, then a choppy consolidation between roughly the mid‑$150s and high‑$190s from late 2023 as the stock repeatedly failed to sustain moves above the $190–$200 area.

In 2024, Zoetis traded mostly in a wide range: after starting the year around the high‑$180s, it rallied near $200 in February before dropping into the high‑$150s in April and then oscillating between the mid‑$160s and low‑$190s for much of the year. Investor sentiment became more nuanced, weighing Zoetis' strong margins and moat against concerns about slowing growth and the need for newer products (including osteoarthritis pain treatments) to sustain its premium profile. This produced a technically sideways, range‑bound phase where the stock repeatedly tested resistance in the high‑$180s–$190s but lacked a catalyst to break decisively to new highs.

2025: Product‑specific scrutiny and guidance shocks

By early 2025, Zoetis shares were again trading in the mid‑$160s–$170s, down from late‑2024 levels near $175–$195, as concerns emerged around safety scrutiny and adoption of its osteoarthritis (OA) franchise (e.g., Librela/Solensia), which had been positioned as an important growth driver. Commentary notes that 2025 results showed about 6% revenue growth and 7% adjusted net income growth, but shareholder returns over the prior year were down more than 20%, reflecting a derating driven by OA‑related sentiment, growth deceleration and a broader derating of high‑multiple defensives.

In Q3 2025 Zoetis reported adjusted EPS of $1.70, beating the $1.62 consensus, but revenue of $2.4 billion slightly missed expectations of $2.41 billion, and management cut revenue guidance, triggering a roughly 15% pre‑market share drop to around $123 on the day. That event was a clear technical breakdown: the stock sliced through prior support levels in one move, reinforcing investor concerns about slowing top‑line momentum and the OA franchise narrative, even though earnings themselves remained solid. While full‑year 2025 adjusted EPS still grew (with 2025 adjusted earnings of $6.41 per share, up from $5.92, and revenues up roughly 2% to $9.47 billion and beating estimates), the market reaction underscored that multiple compression and future‑growth worries, not current profitability, were driving the stock.

Late 2025–early 2026: Derated high‑quality name with strategic moves

Into late 2025 and early 2026, analysis described Zoetis as a financially strong compounder whose valuation reset looked excessive unless long‑term growth was structurally impaired, and highlighted that the stock traded materially below some fair‑value estimates despite still‑robust sector growth prospects. The narrative at this point is a derated, high‑quality animal‑health leader: still commanding strong margins and a durable moat, but with investor focus squarely on OA‑franchise sentiment, regulatory scrutiny, and whether management can re‑accelerate growth into the mid‑single‑digits to high‑single‑digits range it guided for 2026 (management guiding 3–5% 2026 growth with an EPS midpoint above consensus).

Technically, after the Q3 2025 gap‑down to the low‑$120s, the stock experienced volatile trading with attempts to stabilize and rebound, leaving it significantly below the mid‑$150s–$190s range of 2023–2024 and culminating in the current price of 115.93 on March 25, 2026, well off its 2021 peak above $240 but still far above pre‑2019 levels.

Strategically, Zoetis continues to invest in diagnostics and precision animal health, exemplified by the March 2026 agreement to acquire Neogen Corp.'s animal genomics business for $160 million to bolster its precision livestock and genomics capabilities. This acquisition aligns with management's focus on expanding the precision and data‑driven side of the portfolio and may help rebuild a growth narrative around innovation beyond OA pain products over the medium term.

From an investor‑perception standpoint, Zoetis now sits in a "show‑me" phase: widely recognized as a high‑quality animal‑health franchise, but with sentiment and the chart both reflecting skepticism about near‑term growth and product‑specific risks, consistent with a stock that has de‑rated to markedly lower levels such as 115.93 despite solid underlying economics.